1 in 5 of Americans don’t know about new omicron-targeting COVID boosters, survey finds
admin About half of the American public has heard little or nothing about the new COVID-19…
Read MoreBiotechnology
Global tally of COVID cases down 11% in latest week as fatalities fall 18%; BA.5 remains dominant strain
The global tally of COVID cases fell 11% in the week ending Sept. 25 from…
Read MoreGlobal tally of COVID cases down 11% in latest week as fatalities fall 18%; BA.5 remains dominant strain
The global tally of COVID cases fell 11% in the week ending Sept. 25 from…
Read MoreStock of psychedelics company MindMed slides 50% after it sells fresh shares
Shares of psychedelics company Mind Medicine Inc. slid 50% Wednesday, after the company priced a…
Read MoreU.S. and WHO commit to new fund for pandemic prevention and preparedness and urge world leaders to back it
The heads of the U.S. Department of Health and Human Services and the World Health…
Read MoreU.S. and WHO commit to new fund for pandemic prevention and preparedness and urge world leaders to back it
The heads of the U.S. Department of Health and Human Services and the World Health…
Read MoreGetting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive…
Read MoreRegulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read MoreEisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read More